





VENABLE



Technology: Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim. It stimulates bone marrow to produce neutrophils (a type of white blood cell) to fight infection.

	Amgen v. Apotex 0:15-cv-61631 (S.D. Fla.) '784 Patent settled, '138 Patent not infringed, not unenforceable, invalidity dismissed Fed. Cir. 17-1010 Affirmed	Amgen v. Sandoz 2:16-cv-01276 (D.N.J.) (BPCIA declaratory judgment suit, infringement / invalidity not alleged) Voluntarily dismissed	Amgen v. 3 3:16-cv-0 (N.D. C Summ judgment o infringeme Cir. 18-7 Affirmed, F for en b rehearing g in-part, den part	02581 Cal.) of non- ont; Fed. 1552 Petition oanc granted- nied-in-	<i>Amgen v.</i> <i>Apotex</i> 0:18-cv- 61828 (S.D. Fla.) Stipulated dismissal	Apotex v. An IPR2016-01 FWD (All cla unpatentabl request for reh Request for D Review den Fed. Cir. 19- Reversed (No unpatental	542 aims le on earing); irector nied; -2171 claims	Kashiv BioSciences v. Amgen IPR2019- 00791 Settled after institution	Fresenius Kabi v. Amgen IPR2019- 00971 Institution denied	Fresenius Kabi v. Amgen IPR2020- 00314 Settled prior to institution decision	<i>Lupin v. Amgen</i> IPR2021- 00326 Institution denied	
5,824,784	х	х	Х									
8,940,878		Х	Х					х				
8,952,138	Х					Х						
9,856,287					Х				Х	Х	Х	
	Amgen v. Coherus 1:17-cv-00546 (D. Del.) Dismissed for failure to state a claim; Fed. Cir. 18-1993 Affirmed	2:17-cv- (W.D. '997 Patent s of non-infri '707 Patent ju			v. Amgen cv-00977 D. Cal.) intarily nissed	Amgen v. Hospira 1:20-cv-00201 (D. Del.) Settled	Kashiv BioSciences v. Amgen IPR2019-00797 Settled after institution				<i>Pfizer v. Amgen</i> IPR2021-00528 Settled after institution	
8,273,707	х	Х	Х			Х	X				Х	
9,643,997		Х			х			х	х			

